Associations of tTMB and Mutational Status With Clinical Outcomes in Patients With Advanced PD-L1–Positive NSCLC Treated With Pembrolizumab vs Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Ann. Oncol 2023 Apr 01;34(4)377-388, TSK Mok, G Lopes, BC Cho, DM Kowalski, K Kasahara, YL Wu, G de Castro, HZ Turna, R Cristescu, D Aurora-Garg, A Loboda, J Lunceford, J Kobie, M Ayers, MC Pietanza, B Piperdi, RS HerbstFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.